ProCE Banner Activity

Targeting BCMA in Myeloma With CAR T-Cell Therapy

Clinical Thought
Natalie S. Callander, MD, examines the potential and the challenges of CAR T-cell therapy targeting BCMA in patients with multiple myeloma.

Released: September 22, 2020

Expiration: September 21, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Celgene

Faculty Disclosure

Primary Author

Natalie S. Callander, MD

Director, Myeloma Clinical and Cellular Therapy Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has disclosed that she has received funds for research support from Cellectar.